Vystar Corp
Vystar Corp is a U.S.-based company built around two product families: Vytex natural rubber latex materials and RxAir UV-C air purification devices. Its business combines materials development, product commercialization, and licensing/distribution activities across industrial, healthcare, and consumer-oriented end markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueUltra-low protein latex and related rubber materials used in dipped products and other latex applications.
UV-C filterless air purification devices sold for residential, healthcare, and commercial use.
Replacement cartridges and related consumables for previously sold RxAir units.
Market development, distribution, and license-based commercialization of Vytex and related technologies.
Products
Reported · share of revenue- Air Purification Units84.9 %
- Royalties and Other10.8 %
- Mattresses and Toppers4.3 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Vystar sells to manufacturers that use natural rubber latex in dipped goods and other rubber-intensive applications, especially where low-protein or specialty latex properties matter. Its RxAir products are sold through distributors, online channels, and retail outlets to residential buyers, healthcare users, and commercial customers seeking UV-C air purification. The company also serves replacement-part buyers for installed RxAir units and trial customers evaluating Vytex materials for manufacturing use.
Buy Vytex materials for dipped products and other latex applications where protein content and material performance matter.
Buy RxAir units for air purification in environments that value germicidal UV-C performance and FDA-cleared products.
Buy RxAir residential purifiers for home air cleaning without traditional filters.
Buy larger or commercial RxAir units for offices, facilities, and other shared spaces.
Buy ViraTec cartridges for previously sold units, supporting the installed base.
Strategy
Vystar’s strategy centers on commercializing Vytex through trials, distribution partnerships, and licensing while expanding RxAir through newer product versions and broader channel coverage. It is also pursuing structural options for its divisions, including potential spinouts, sales, or other transactions, to unlock value and focus capital on the most scalable opportunities. Product development remains important, with efforts aimed at new air purifier formats and additional Vytex applications.
Vytex needs customer adoption and manufacturing validation to become a scalable materials business.
Broader product availability and channel coverage can support recurring device and cartridge sales.
Spinouts or sales may help separate businesses with different capital needs and commercialization paths.
Geography
Vystar is headquartered in the United States and its commercial activity is centered there, including product development, manufacturing coordination, and domestic sales channels. The company also references contract manufacturing and production options in other geographies for Vytex supply lines, which can affect sourcing, logistics, and tariff exposure. Its customer reach is broader than one country, but the available disclosures emphasize U.S.-based operations and North American market needs.
Risks
Vystar faces execution risk because its businesses depend on customer trials, commercialization milestones, and continued access to financing. It also has exposure to tariff and supply-chain disruption, product adoption uncertainty, and the challenge of scaling niche technologies into repeatable revenue streams. As a small company with limited operating scale, delays in product acceptance or capital formation can materially affect continuity and growth.
The company depends on external financing and product monetization to fund operations.
Exposure: Cash on hand and working capital
Vytex relies on trials, customer validation, and manufacturing-scale adoption before it can generate durable demand.
Exposure: Industrial latex and dipped-product markets
Air purifier sales depend on channel execution, regulatory positioning, and customer acceptance of UV-C technology.
Trade policy and import tariffs can raise input costs and disrupt sourcing or contract manufacturing decisions.
Exposure: Imports from China and other countries
Accounting
Judgemental itemsSales can be lumpy because they depend on bulk orders, trial shipments, and channel activity.
Impact: Quarterly comparability
Share-based awards are a significant operating expense and affect reported losses.
Impact: Operating expense and net loss
Limited liquidity and recurring losses require management judgment about continuation assumptions.
Impact: Financial statement presentation and risk disclosure
Past or future business separations can reclassify results and affect trend analysis.
Impact: Comparability across periods
Similar listed companies
Publicly listed companies with a comparable business focus.
Liquidia Corp
LQDA · Pharmaceutical Preparations
Liquidia Corp is a U.S.-based biopharmaceutical company focused on rare cardiopulmonary diseases, especially pulmonary arterial hypertension (PAH) and…
Jasper Therapeutics, Inc.
JSPR · Biological Products, (No Diagnostic Substances)
Cytosorbents Corp
CTSO · Surgical & Medical Instruments & Apparatus
Cytosorbents Corp develops blood purification and adsorption devices used in critical care, cardiac surgery, and other acute care settings.
Ouster, Inc.
OUST · General Industrial Machinery & Equipment, NEC
Waystar Holding Corp.
WAY · Services-Computer Integrated Systems Design
RLX Technology Inc.
RLX · Cigarettes
Last updated: 29/04/2026